CLINICAL_TRIALS
ClinicalTrials.gov record update
Tolerating Subretinal Fluid in Type 1 Macular Neovascularization and Polypoidal Choroidal Vasculopathy Treated Using Aflibercept
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05662943
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:24.917648+00:00
- Published At
- 2023-12-14T00:00:00+00:00
- Record Updated At
- 2023-12-14
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Polypoidal Choroidal Vasculopathy", "Choroidal Neovascularization", "Age-Related Macular Degeneration"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-12-14"- protocolSection.identificationModule.nctId
"NCT05662943"- protocolSection.identificationModule.officialTitle
"Tolerating Subretinal Fluid in Type 1 Macular Neovascularization and Polypoidal Choroidal Vasculopathy Treated Using Aflibercept"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
[]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.